GGHC
TXG icon

Gilder Gagnon Howe & Co’s 10x Genomics TXG Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-24,394
Closed -$474K – 271
2024
Q2 		$474K Sell
24,394
-479,780
-95% -$12.6M 0.01% 234
2024
Q1 		$18.9M Buy
504,174
+1,703
+0.3% +$74.8K 0.24% 89
2023
Q4 		$28.1M Buy
502,471
+3,350
+0.7% +$146K 0.39% 65
2023
Q3 		$20.6M Buy
499,121
+473,845
+1,875% +$24.7M 0.31% 74
2023
Q2 		$1.41M Buy
25,276
+9,566
+61% +$518K 0.02% 216
2023
Q1 		$876K Buy
15,710
+5,588
+55% +$261K 0.01% 200
2022
Q4 		$369K Sell
10,122
-14,580
-59% -$477K 0.01% 224
2022
Q3 		$704K Sell
24,702
-542,785
-96% -$20.7M 0.01% 209
2022
Q2 		$25.7M Sell
567,487
-176,294
-24% -$9.15M 0.46% 61
2022
Q1 		$56.6M Sell
743,781
-22,647
-3% -$1.98M 0.52% 57
2021
Q4 		$114M Sell
766,428
-11,319
-1% -$1.73M 0.65% 49
2021
Q3 		$113M Buy
777,747
+922
+0.1% +$158K 0.59% 55
2021
Q2 		$152M Sell
776,825
-4,810
-0.6% -$871K 0.75% 41
2021
Q1 		$141M Sell
781,635
-15,020
-2% -$2.59M 0.76% 38
2020
Q4 		$113M Buy
796,655
+108,044
+16% +$15.7M 0.56% 57
2020
Q3 		$85.9M Buy
688,611
+169,443
+33% +$17.8M 0.53% 64
2020
Q2 		$46.4M Buy
+519,168
New +$40.4M 0.36% 82

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Gilder Gagnon Howe & Co's TXG Position: Q3 2024 in Review

Gilder Gagnon Howe & Co sold out of 10x Genomics (TXG) in Q3 2024, closing a stake of 24,394 shares — an estimated $474K sold.

Gilder Gagnon Howe & Co first reported a position in TXG in Q2 2020 and held it in 17 quarters. The position peaked at $152M in Q2 2021. 266 funds tracked by Wall St. Rank hold TXG as of Q3 2024.

  • Gilder Gagnon Howe & Co reported no remaining 10x Genomics position as of Q3 2024 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 24,394 10x Genomics shares in Q3 2024, an estimated $474K.
  • Gilder Gagnon Howe & Co first reported a position in 10x Genomics in Q2 2020 and held it in 17 quarters.
  • Gilder Gagnon Howe & Co's 10x Genomics position peaked at $152M in Q2 2021.
  • 266 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2024.

Based on Gilder Gagnon Howe & Co's 13F filing for Q3 2024, filed 14 Nov 2024.